CD274 and triple-negative breast carcinoma: Based on data from Impassion130 (NCT02425891), atezolizumab (anti-programmed cell death 1 ligand 1, anti-PD-L1 mab, Roche) has been approved by the FDA in March 2019 for the treatment of advanced or metastatic triple-negative breast cancer (TNBC) patients with tumor-infiltrating immune cells expressing PD-L1 (≥1%, tumor area) [3].